Fernanda Damian

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

Adi Diab, Helen Gogas, Shahneen Sandhu et al. · Journal of Clinical Oncology · 2023 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Danny Rischin, Sandro Porceddu, Fiona Day et al. · New England Journal of Medicine · 2025 · 60 citations

Medicine, Oncology, Pharmacotherapy +17

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote et al. · Annals of Oncology · 2021 · 41 citations · Full text

Medicine, Biomedical Sciences, Oncology +16